Guided Solutions’ Post

🫀🤝Edwards Lifesciences continues their M&A spree with yet another #structuralheart acquisition, by way of Genesis Medtech Group and their JC Medical, Inc. subsidiary. The newly announced #acquisition will bring JC Medical, Inc.’s J-valve transcatheter #aortic valve replacement (TAVR) system under Edward’s rapid growing portfolio which includes recent acquistions of Innovalve Bio Medical Ltd., JenaValve Technology, Inc., Endotronix, and significant investment into Affluent Medical. Edward’s has not yet disclosed financial details however this new deal adds to over $1.5B USD in M&A activity this year along and counting. “J-Valve has unique advantages in treating aortic valve regurgitation. We hope that J-Valve can expand its global impact, enabling more patients to benefit from this innovative product. We will continue strengthening our focus on developing innovative products and explore better medical solutions to benefit more patients worldwide." - Warren Wang, Chairman & CEO of Genesis Medtech Group #medtechmoney #mergersandacquisitions #structuralheart #medtechdeals The Mullings Group

Big News in Medtech: Edwards Sets Acquisition Sights on Innovalve & Affluent Medical Stake Following a recent divestiture, Edwards is doubling down on owning the structural heart space. On Monday, Edwards announced exciting plans to acquire Innovalve Bio Medical, an Israel-based startup specializing in transcatheter mitral valve replacement (TMVR) technologies. With a forecasted closing by the end of the year, this acquisition represents a $300 million investment in advancing cardiovascular health. But that's not all. In a separate but equally strategic move, Edwards has also declared a €15 million (~$16.3 million) agreement with Affluent Medical. This deal gives Edwards a 9.21% equity stake in the French company and includes an exclusive option to acquire Affluent's Kephalios subsidiary, which specializes in adjustable cardiac mitral rings, and a global license for their biomimetic mitral valve replacement technology. The investment further underscores Edwards' commitment to expanding its portfolio in the mitral valve space. This dual acquisition strategy couldn't come at a more opportune time. Earlier this year, Edwards achieved a significant milestone with their Evoque device receiving FDA approval as the first transcatheter treatment for tricuspid regurgitation, eliminating the need for open-heart surgery. Edwards' new moves to purchase Innovalve and invest in Affluent Medical's technologies show their dedication to treating complex mitral diseases with a more differentiated range of therapies. So, what does this mean for us in the Medtech community? It's a demonstration of how strategic acquisitions and partnerships can drive innovation and expand treatment options for patients. Let's continue the conversation—what are your thoughts on Edwards' latest moves? #Medtech #Cardiology #Innovation

BREAKING NEWS FROM THE HEALTHCARE INDUSTRY Johnson & Johnson acquired Shockwave Medical - Johnson & Johnson's latest acquisition of Shockwave Medical Inc. for an estimated $13.1 billion in enterprise value marks a significant stride in its quest to dominate the medical devices market, particularly in heart disease treatments. This move comes as J&J pivots away from its consumer health division, focusing instead on fortifying its medical technology prowess. Previous acquisitions, including heart-assist device maker Abiomed and atrial fibrillation treatment innovator Laminar, underscore J&J's ambition to lead in crucial, fast-expanding cardiovascular technology niches. - Shockwave Medical brings to J&J's portfolio the revolutionary intravascular lithotripsy technology, which employs sound waves to disintegrate calcifications within heart vessels and peripheral circulation. Touted for its safety over traditional treatments, this technology represents a leap forward in cardiac care, potentially setting new treatment standards. - Speculation around Shockwave's acquisition has been rife, with notable interest from industry peers like Boston Scientific Corp. This deal propels Shockwave shares upward, a trend observed with a 68% increase since the year's start, reflecting the market's optimistic outlook on this merger. Meanwhile, J&J's share response in premarket trading indicates a cautious but positive investor sentiment. - To finance this substantial acquisition, J&J plans to utilize a combination of cash on hand and debt, signaling confidence in leveraging its financial resources for strategic expansion. However, the acquisition is anticipated to slightly dilute J&J’s earnings per share in the immediate future, with a projected impact of about 10 cents on an adjusted basis in 2024 and 17 cents the following year, inclusive of a $448 million termination fee. This short-term financial impact highlights the strategic nature of this acquisition, focusing on long-term growth over immediate earnings. - This aggressive expansion into medical technology and drug development is partly driven by J&J’s proactive measures to mitigate the potential financial impact of its top-selling drug, Stelara, losing US exclusivity next year. The acquisition of Ambrx Biopharma Inc., earlier this year for approximately $2 billion, further emphasizes J&J's commitment to diversifying its portfolio, particularly in the promising field of antibody-drug conjugates. - The strategic advise from J.P. Morgan to J&J and Perella Weinberg to Shockwave underscores the meticulous planning and expertise behind this acquisition, reflecting both companies' dedication to advancing healthcare through innovative medical technologies. #johnsonsndjohnson #shockwavemedical #healthcareindustry #strategicacquisition #mergersandacquisitions #marketanalysis

Boston Scientific is set to acquire Silk Road Medical, Inc. for $1.16 billion, paying $27.50 per share. This acquisition enhances Boston Scientific's portfolio with Silk Road's #TCAR system, a revolutionary #stroke prevention technology. Expected to close in H2 2024, the deal aligns with Boston Scientific's strategy of expanding its vascular innovations. Silk Road Medical projects $194-198 million in 2024 revenue, continuing its growth trajectory. This move marks another significant M&A for Boston Scientific, following recent acquisitions in the #medtech space following had just announced the acquisition of Relievant Medsystems, Inc. Medsystems, which it completed in November. In January, Boston Scientific announced its plans to buy Axonics, Inc. and its #neuromodulation and #hydrogel technologies. Those two deals combined totaled costs of more than $4.5 billion ($3.7 billion for Axonics, $850 million for Relievant). However, the Axonics deal has yet to be completed after the FTC requested more information on the acquisition in April. Sean Whooley MassDevice https://lnkd.in/e9s__5Cr

Shockwave Medical: The Billion-Dollar Game Changer for J&J MedTech   Johnson & Johnson's Q2 earnings report highlights their acquisition of Shockwave Medical, set to add $500 million in sales by year-end. In just the first 30 days, Shockwave contributed $77 million, showcasing its immediate impact. Chalk, Borrowed from Shockwave’s website:  “In 2009, a marketer, engineer and cardiologist came together to change the nature of interventional therapy for calcified cardiovascular disease. They envisioned a future in which lithotripsy, a trusted technology used to break kidney stones for more than three decades, could be adapted to crack calcium in undilatable lesions in a potentially easier and safer manner. What started out as a crazy idea is now changing the standard of care for patients with calcified disease around the globe.” Have you ever seen a medical device’s revenue ramp up as fast? Share your experience in the comment below. “We closed that transaction in record timing, and we are really excited to shortly announce that they will be the 13th business with sales in excess of $1 billion annually,” added J&J MedTech’s worldwide chairman, Tim Schmid. Find more details in the article linked in the comments. #Biotechnology #HealthcareInnovation #MedTech #JohnsonAndJohnson #ShockwaveMedical #CardiovascularHealth #MedicalAdvancements #HealthcareTech #Innovation #LifeSciences 

More huge news landed in the MedTech industry yesterday! And no, I’m not talking about the announcement of our latest guest on Inside MedTech! (Although there is a connection). One of our guests previous companies Johnson & Johnson will acquire V-Wave in a deal worth up to $1.7bn. J&J spoke about being agressive in their M&A this year and hot on the heels of the Shockwave Medical acquisition, they have further strengthened their cardiovascular capabilities. Both acquisitions follow the purchase of Abiomed last year and further cements J&J as a real powerhouse in the industry. They have said this will further "accelerate its shift into high-growth and high-opportunity markets and will deepen its relationships with structural interventional cardiologists and heart failure specialists," Huge news and with the latest spate of M&A activity in MedTech, there are promising signs for the industry. Congrats to all involved. Keep on making a difference! #medtech #insidemedtech #medtechacquisition #cardiovascular

M&A: Alcon Acquires BELKIN Vision for $81M - HIT Consultant #MergersAndAcquisitions: Alcon Acquires BELKIN Vision for $81M In a recent development, Alcon has acquired BELKIN Vision for $81M, expanding its presence in the healthcare IT market. The acquisition aims to enhance Alcon's portfolio of vision care solutions and strengthen its position in the industry. #StrategicPartnership: Alcon's Acquisition Strategy Alcon's acquisition of BELKIN Vision is part of its strategic partnership approach to grow its business and offer innovative solutions to customers. By joining forces with BELKIN Vision, Alcon aims to leverage their expertise and technology to drive growth and improve patient outcomes. #ImpactOnHealthcareIT: Enhanced Vision Care Solutions The acquisition ai.mediformatica.com #vision #acquisition #technology #this #integration #market #physicians #eyecare #management #outcomes #patientcare #patients #digitalhealth #healthit #healthtech #healthcaretechnology @MediFormatica (https://buff.ly/3xD12Mn)

🩸💵 More and more #medtech #funding moving into the start of November as Inquis Medical, Inc. out of Menlo Park, CA announces $40M in new #financing toward their Aventus Precision Thrombectomy System. Inquis Medical, Inc.'s latest oversubscribed Series B round was led by Marshall Wace alongside legacy #investors ShangBay Capital, Yu Star, EnPointe Ventures, and Pierre Lamond; with earmark toward completing their pivotal IDE expanding #clinical indications to include #pulmonary embolism (PE) patients for their proprietary tissue-sensing #thrombectomy technology. “This substantial investment from Marshall Wace, along with our existing investors, underscores a strong belief in both our technology and our team. We are excited for the next phase of the company and look forward to enhancing patient care by empowering physicians with our unique technology.” - Mojgan Saadat, Inquis Medical, Inc. Co-CEO & Co-Founder #medtechmoney #privateequity #venturecapital #medicalinnovation The Mullings Group

Strategy and its execution. Bravo, Johnson & Johnson. Bold statement. $30 billion in planful M&A activity is nothing to sneeze at, particularly with the numbers quoted on the year-over-year performance for cardiology. This is very much a long view. And it looks like JNJ has the talent bench to actually get the job done - since “M&A is easy, but integration is hard.” Other interesting takeaways for me: ✅ RECORNEA’s announcement about its #keracotonus treatment ✅ the two gastric mentions, including the device that passes naturally after displacing stomach volume (hence food capacity) ——— Social media allows folks like Holly Scott and their thinking to be available. Sunday morning wouldn’t be Sunday morning for me without a cup of coffee and Holly’s curation. Who speaks into your professional life? Who do you seek out? I look for Kevin Berchelmann, Matthew Ray Scott, Bryan Sagray and Joe Mullings. How about you? #leadership #changinglives #dothething

Really interesting article published by Chris Newmarker from MassDevice highlights the top medtech stories of the year so far. In a year full of exciting M&A's, I agree with the author's view that the rise of pulsed-field ablation in the US takes the top spot. Given the numerous FDA approvals in PFA for Medtronic, Boston Scientific and Johnson & Johnson coupled with Abbott first global procedures for its Volt system, PFA really has been the centre of attention within the #Epeeps community. What MedTech stories of the year interested you the most? #medtech #medicaldevices #pfa